The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus
Table 1
Change of biochemical index after metformin or canagliflozin treatment.
Metformin
Canagliflozin
valueb
Pretreatment
Posttreatment
%change
valuea
Pretreatment
Posttreatment
%change
valuea
Weight (kg)
0.04
0.363
-2.5
<0.001
0.233
SBP (mmHg)
-3.3
0.356
-3.7
0.138
0.902
DBP (mmHg)
-3.6
0.356
-4.5
0.116
0.837
HbA1c (%)
-15.6
0.001
-18.8
<0.001
0.319
ALT (U/L)
-20.6
0.045
-28.8
0.01
0.342
AST (U/L)
-2.9
0.779
-21.5
0.009
0.103
GGT (U/L)
-25.7
0.043
-20.2
0.001
0.574
ALP (U/L)
-9.4
0.02
-8.3
0.002
0.384
TBIL (μmol/L)
-6.6
0.257
-17.5
0.014
0.227
DBIL (μmol/L)
-1.9
0.751
-5.3
0.19
0.543
TBA (μmol/L)
9.1
0.49
10.0
0.299
0.840
GLU (mmol/L)
-20.7
0.007
-22.1
<0.001
0.773
C-peptide (ng/mL)
-21.6
0.067
-7.5
0.129
0.357
Insulin (mU/L)
-32.6
0.152
-15.2
0.208
0.259
K (mmol/L)
35.4
0.323
-0.5
0.746
0.220
Na (mmol/L)
0.03
0.946
-0.1
0.859
0.867
CL (mmol/L)
0.4
0.406
-2.6
0.336
0.361
Ca (mmol/L)
0.9
0.462
-0.8
0.175
0.155
P (mmol/l)
0.9
0.744
3.6
0.153
0.478
Mg (mmol/L)
-3.4
0.448
3.5
0.171
0.217
Cr (μmol/L)
5.2
0.035
2.3
0.249
0.409
BUN (mmol/L)
-7.9
0.079
8.0
0.048
0.042
UA (μmol/L)
7.4
0.048
-15.5
<0.001
0.012
Lipid profile
TG (mmol/L)
5.2
0.653
-8.3
0.662
0.079
TC (mmol/L)
-5.4
0.172
-3.8
0.151
0.740
HDL-c (mmol/L)
-1.6
0.577
9.1
0.005
0.024
LDL-c (mmol/L)
-4.6
0.210
-6.1
0.236
0.821
ANGPTL3 (ng/mL)
-3.5
0.579
-22.7
<0.001
0.015
ANGPTL4
—
—
—
—
-9.7
0.215
—
ApoA1
—
—
—
—
-0.5
0.726
—
a value for the intragroup comparison (pre- vs. posttreatment values in metformin or canagliflozin group). b value for intergroup comparison (metformin vs. canagliflozin group in the changes from pre- to posttreatment).